Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal Function
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Renal Impairment and in Those With Normal Renal Function
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of DA-302168S in subjects with moderate renal impairment (with the possible inclusion of subjects with mild renal impairment), compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations for DA-302168S in subjects with renal impairment.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: xiaolong qin
- Numéro de téléphone: 18781997925
- E-mail: qinxiaolong.cn@outlook.com
Lieux d'étude
-
-
Jiangsu
-
Suzhou, Jiangsu, Chine, 215000
- Recrutement
- The Second Affiliated Hospital of Soochow University
-
Contact:
- xiaolong qin
- Numéro de téléphone: 18781997925
- E-mail: qinxiaolong.cn@outlook.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18-65 years inclusive at ICF signing, male or female; age matching (±10 years) between normal and renal impairment groups, with sex matching as far as possible (±1 participant per sex).
- Weight and BMI at screening: male ≥50.0 kg, female ≥45.0 kg; BMI 19.0-30.0 kg/m² inclusive; weight matching (±10 kg) between normal and renal impairment groups.
- Fertile female or male participants must agree to use reliable contraception for themselves and their partners during the study and for 90 days after dosing (see Appendix 3), and must not donate sperm or oocytes/eggs for assisted reproduction.
- Able to understand the study procedures and methods, voluntarily sign the ICF, and willing to strictly comply with protocol requirements and complete the related procedures.
Exclusion Criteria:
- History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or screening serum calcitonin ≥50 ng/L.
- History of chronic pancreatitis, or acute pancreatitis within 3 months before ICF signing.
- History of acute gallbladder disease within 3 months before ICF signing.
- Any malignancy within 5 years before ICF signing (except curatively treated basal cell carcinoma considered cured).
- History of severe cardiovascular, neuropsychiatric, gastrointestinal, respiratory, urinary, endocrine, or other systemic disease within 1 year before ICF signing (e.g., acute myocardial infarction, major depression, gastric ulcer, uremia).
- Investigator-judged dysphagia at screening, or conditions possibly affecting drug absorption, distribution, metabolism, or excretion (e.g., active inflammatory bowel disease, gastrectomy, any intestinal resection).
- Severe hypoglycemia within 3 months before screening.
- Participation in any clinical trial within 3 months before screening (except ICF signing only without drug/device intervention), or last dose of investigational drug <5 half-lives before screening.
- History of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known intolerance/allergy to GLP-1 receptor agonists.
- Major surgery within 1 year before screening [major surgery defined as surgery on intracranial, thoracic, abdominal, pelvic, or limb organs causing major tissue trauma and requiring prolonged recovery (e.g., organ transplantation, cardiac surgery, joint replacement)], or planned surgery during the study.
- Blood donation or massive blood loss (≥400 mL) within 3 months before screening or between screening and first dose, or planned blood donation during the study.
- History of drug abuse within 3 years before screening (e.g., morphine, ketamine, THC acid, methamphetamine, MDMA, cocaine) or positive baseline urine drug test.
- Smoking >5 cigarettes/day or habitual use of nicotine-containing products within 3 months before screening, or inability to abstain during the study.
- History of alcohol abuse within 1 year before screening (male >14 standard units/week, female >7 standard units/week; 1 standard unit = 14 g alcohol, e.g., 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or positive baseline breath/blood alcohol test.
- Special dietary requirements and inability to accept a standardized diet.
- Consumption of grapefruit-rich beverages or foods within 7 days before first dose, or unwillingness to stop during the study.
- Vaccination within 30 days before dosing, or planned vaccination within 30 days after dosing.
- Inability to avoid strenuous exercise or other behaviors possibly affecting PK parameters from 48 h before dosing through the study.
- History of needle/blood phobia, difficult blood collection, or intolerance to venipuncture.
- Pregnant or lactating women.
- Participant is an investigator or other related research staff for this project.
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Group A
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
Expérimental: Group B
Subjects with moderate renal impairment |
Small molecule GLP-1RA tablet |
|
Comparateur placebo: Group C
Subjects with normal renal function matched to renal impairment subjects |
Small molecule GLP-1RA tablet |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Peak Plasma Concentration (Cmax) of DA-302168S
Délai: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
|
Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of DA-302168S
Délai: Predose up to 72 hours postdose (D1 to D4)
|
Predose up to 72 hours postdose (D1 to D4)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2026-CP-DA168-14
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .